ABSTRACT Cytochrome P450 (P450)-dependent aryl hydrocarbon hydroxylase (AHHase) and 7-ethoxycoumarin deethylase (ECDEtase) in human tissues were differentially inhibited by monoclonal antibodies (MAbs) that were prepared to inhibit and completely inhibited the activity of3-methylcholanthrene-induced rat liver P-450. The AHHase and ECDEtase of placentas from individual women who smoked were inhibited by the MAbs by 83-90% and by 34-74%, respectively. Benz [a]anthracene (BaA)-induced AHHase and ECDEtase in lymphocytes were inhibited 18-65% and 30-78%, respectively. The enzymes in both control and BaA-induced human cells in culture were inhibited to different extents. Both the AHHase and ECDEtase in control and BaAinduced monocytes and in normal liver were largely unaffected by the MAb. Thus, we have with the MAbs: (i) identified P-450s with a common antigenic site in placenta, lymphocytes, and human cells in culture; (ii) identified two forms of hydrocarbon-induced P450s in lymphocytes, at least one of which is common with the induced P450s of placenta and with a P-450 form present in uninduced lymphocytes; (iii) identified two forms of P-450 responsible for smoking-induced ECDEtase activity in placenta, one of which is also responsible for AHHase activity; (iv) shown that the P-450s of liver, basal, and BaA-induced monocytes are different from the MAb-sensitive P-450s of placenta and lymphocytes; (v) quantitated in several human tissues the percentages of control and inducible AHHase and ECDEtase that are dependent on the MAb-sensitive P-450; and (vi) defined by HPLC the contribution of the MAb-sensitive P-450 to the formation of specific benzo[a]-pyrene metabolites. The results demonstrate the value of MAbs for defining antigenic site relatedness for different enzymatic functions ofP450s and for identifying and quantifying the amount of a specific enzyme activity in a tissue dependent on specific P450s. This study may be a prototype for the use of MAbs for phenotyping and mapping of P-450s responsible for specific metabolic reactions and, thus, may be useful in determining the relationship of P450 phenotype to individual differences in drug metabolism and carcinogen susceptibility.
The mixed-function oxidases containing cytochromes P450 metabolize a variety ofxenobiotics and endogenous compounds, including carcinogens, drugs, and steroids (1, 2) . The P-450s govern reactions that lead to detoxified metabolites or to toxic, mutagenic, and carcinogenic compounds (1, 2) . The P-450s convert benzo [a] pyrene (BaP) to an active form that is covalently bound to DNA (3) . The latter system activates xenobiotics to their mutagenic forms in the Ames assay (4). Xenobiotic activation and detoxification may occur through alternative metabolic pathways regulated by different P-450s with overlapping specificities. Thus, BaP is converted by P-450s and linked enzymes, to >40 metabolites (1) . BaP metabolism resulting in activation involves P450-catalyzed epoxidation, followed by formation of (-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene, designated (-)-trans-7,8-diol (1, 5) , which is further oxygenated by P-450 to r-7,t-8-dihydroxy-t-9, 10-oxy-7,8,9, 10 tetrahydrobenzo[a]pyrene, designated diol-epoxide I. The latter binds covalently to DNA and is highly mutagenic (1, 6) . Purified forms of P450 exhibit substrate selectively and product regioselectivity and positional stereoselectivity for BaP and (-)-trans-7,8-diol metabolism (1, 7) . Thus, the distribution of P450s may govern metabolic pathway choice and responsiveness tocarcinogens, drugs, and steroids.
Enzyme purification, kinetic, genetic, inhibitor, and immunological studies have shown a multiplicity of basal and inducible P450s (1, (8) (9) (10) (11) (12) . Enzyme multiplicity and overlapping stereo-and regioselectivity have limited the determination of P-450 phenotype in tissues or individuals. Thus, the precise role ofP-450s in metabolism or activation of specific xenobiotics and in individual variation in drug and carcinogen responsiveness has not been accomplished. Monoclonal antibodies (MAbs) formed by potentially immortal hybridomas are pure and precise probes for specific antigenic sites on enzyme proteins (13, 14) . MAbs that interfere with enzyme activity identify and target proteins functioning in specific reactions. We have prepared and characterized panels of MAbs to a phenobarbital (PB)-induced P-450 (PB-P-450 LM2), a f3-napthoflavone (ANF)-induced P-450 (A3NF-P-450 LM4) from rabbit liver, and a 3-methylcholanthrene (MC)-induced P-450 (MC-P-450) from rat liver. The MAbs to PB-P-450 LM2 and MC-P450 inhibit BaP hydroxylation-i.e., aryl hydrocarbon hydroxylase (AHHase, EC 1. 14.14.1) and 7-ethoxycoumarin deethylase (ECDEtase) ofthe purified P-450s-by more than 90% (15) (16) (17) . The latter MAbs have been used in this study. Other MAbs to PNF-and MC-P-450 that bind but either do not inhibit enzyme activity or inhibit by -40% also have been prepared by us (15) (16) (17) and another laboratory (18) . Human placenta from women who smoke cigarettes are induced for AHHase and ECDEtase, both P450 enzymes (19) (20) (21) . The placenta from nonsmokers have either undetectable or lower levels of these enzymes. Kinetic, inhibitor, and genetic studies suggest two forms of P-450 for ECDEtase activity in human placenta and mouse liver (19, 20, 22) and two forms of AHHase in mouse liver (23 (31) . The fractions were collected, and radioactivity was measured in a Beckmann model 7000 scintillationcounterwithAquasol (New England Nuclear). Identification of each metabolite was verified by cochromatography with authentic reference standards.
Preparation of Monoclonal Antibodies against MC-P-450.
MAbs were prepared by the hybridoma method of Koehler and Milstein (14) . The detailed preparation and characterization have been described (15) (16) (17) . Female BALB/c mice were immunized with either MC-P-450 (from F. Guengerich) purified from the livers of MC-treated rats, or with PB-P-450 LM2 (from M. J. Coon) from PB-treated rabbits. Hybrid cells were selected through several passages and cloned (15) (16) (17) . The culture supernatants were screened for antibody production by radioimmunoassay and inhibition of AHHase (15) (16) (17) . The hybridoma cells selected for the production of the desired antibodies were resuspended in phosphate-buffered saline and inoculated intraperitoneally into BALB/c female mice primed with pristane (2,6,10,14-tetramethylpentadecane; Aldrich) (32) and ascites fluids were collected after 2 or 3 wk.
RESULTS
Effect of MAbs to Rat Liver MC-P-450 and Rabbit Liver PB-P-450 LM2 on AHHase and ECDEtase of Human Placenta. Twelve MAbs have been prepared to purified MC-P-450 isolated from rat liver that bind to the purified antigen MC-P-450 as shown by a positive radioimmunoassay (15) . Three of these MAbs, 1-7-1, 1-8-1, and 1-31-2, completely inhibit the AHHase and ECDEtase activity ofpurified MC-P-450 and 70% ofthe activity ofmicrosomes from MC-treated rats. They do not inhibit or bind to the major P-450 from PB-treated rats or rabbits or to microsomes from control or PB-treated rats. Another MAb, 1-26-11, inhibited the AHHase and ECDEtase activity of purified PB-P-450 LM2 but did not bind or inhibit fNF-P-450 LM4 or MC-P-450. The isolation and characterization of these classes of MAbs have been described (15) . Tables 1 and  2 show that saturating levels of the three MAbs that inhibited the purified MC-P-450 and liver microsomes from MC-treated rats also inhibited the AHHase of placenta by 83-95%. However, the same MAbs inhibited placental ECDEtase activity to a far lesser extent (21-74%). Nine other MAbs that bound but did not inhibit the purified MC-P-450 also did not inhibit the placental enzymes. The MAb 1-26-11, which inhibited the purified PB-P450 LM2, failed to inhibit either AHHase or ECDEtase activity of the human placenta. Fig. 1 (33, 34) . However, the latter studies have not been confirmed in twin and lung cancer patients (35) (36) (37) , and the questions raised by the latter studies remain unanswered (38) the inhibitory effects of MAb 1-7-1, indicating that AHHase and ECDEtase in monocytes are catalyzed by a P-450 different from the MAb 1-7-1 sensitive P450 of human placenta and lymphocytes. In a previous study (39), we reported that polyclonal rabbit antibodies to rat liver MC-P-450 inhibited both BaA-induced lymphocytes and monocytes. The present study demonstrates the high specificity of the monoclonal antibody compared to ordinary polyclonal rabbit antibodies. The P-450-catalyzed ECDEtase of microsomes from individual normal human liver was entirely unaffected by MAb 1-7-1, indicating its difference Table 3 . HPLC analysis of BaP metabolites (pmol) formed by placenta, antibody 1-7-1 MC-P-450 from the MAb-sensitive P-450s present in lymphocytes and placenta. The moderate inhibition ofAHHase in certain individual human livers may reflect the presence of a low level of MAbsensitive P-450. Table 2 also shows that both control and BaAinduced HeLa cells were inhibited by 72%. The AHHase activity of A549 cells was inhibited by only 11-15%, and the Detroit 98 cells showed a low level of uninduced AHHase, which was inhibited by 67%, and a nine-fold greater level of BaA-induced AHHase, which was only slightly inhibited. Our results show that there are at least two forms of BaA-induced P-450 in human tissues. One of these forms is induced in placenta by smoking and in lymphocytes by BaA and is sensitive to MAb 1-7-1. The other form is insensitive to MAb 1-7-1 and is the predominant and perhaps only form present in both control and induced monocytes and Detroit A549. The latter P-450 may be identical to the second form present in placenta and lymphocytes that is insensitive to MAb 1-7-1.
HPLC Analysis of MAb Inhibition of BaP Metabolism. Several studies have analyzed human placental and lymphocyte BaP metabolism (21, 31, 40) . Table 3 shows that the formation of the 7,8-diol, the 9,10-diol, the 7-hydroxy, 9-hydroxy, 1-and 3-hydroxy, and quinone metabolites were inhibited by the MAb 1-7-1 from 65% to 100%. The formation of the 4,5-diol metabolite was inhibited by only 28% and the 7-hydroxy formation was not inhibited. This suggests at least two forms of placental P-450s, each with different positional specificities. Variation in MAb inhibition of metabolite formation was also observed with BaA-induced lymphocytes. Here, there was a total absence of MAb inhibition of quinone formation, suggesting that quinones are the result of reactions entirely independent of the P-450 sensitive to MAb 1-7-1. With induced monocytes, total metabolism was inhibited by 18% with some differences among metabolites. The HPLC analysis shows the efficacy of MAb for determining the P-450 responsible for specific reactions occurring at different positions of the substrate. Table 4 summarizes the results of our study with MAbs. (i) We identified an antigenic site that is common to P-450s present in human tissues-i. e., placenta, lymphocytes, some liver samples, and several cells in culture-and to MC-P-450 of rat liver.
DISCUSSION
(ii) Eighty-three to 92% of the AHHase induced in placenta by smoking is dependent on a single P-450 or a family of P450s sharing a common MAb-sensitive antigenic site. The same P-450 is responsible for only part (38-74%) phocytes also contain at least two forms ofP-450 responsible for AHHase and ECDEtase. One of these P-450s, sensitive to the MAb, shares an antigenic site and may be identical to the induced form sensitive to MAb. (iv) Both control and induced lymphocytes contain a P-450 sharing an antigenic site with a P-450 in induced placenta. (v) Both control and hydrocarbon-induced monocytes and some normal livers do not contain the MAb-sensitive P450 present in induced placenta and in both control and induced lymphocytes. Thus, monocytes and liver contain different P-450s for both AHHase and ECDEtase that are insensitive to the MAb. (vi) Variations in MAb inhibitory activity in induced placenta and in control and induced lymphocytes from different individuals may reflect genetically determined control of the amount of the MAb-sensitive form of P-450 in these individuals. Our studies show that a library of MAbs can be used for the preparation ofan atlas ofP-450s identified by different antigenic sites. Furthermore, the MAbs can identify drug and xenobiotic reactions for which different cytochromes P-450 are responsible. Our studies do not contain the number of samples sufficient to determine whether the individual differences observed are genetic, or environmentally determined. Studies with MAbs will permit genetic analysis of P450 phenotype in individuals. Our results also show the efficacy of the MAbs for determining the role of specific P-450s in metabolism at a given site on a substrate. Thus, BaP conversion to quinones in lymphocytes was totally unaffected by the MAbj whereas formation of phenols and diols was inhibited.
The P450s are the enzyme interface between higher organisms and environmental chemicals, drugs, and many endogenous metabolites. Biochemical individuality in responsiveness to these agents is complex and relates to both environmental and genetic factors. The MAbs will be generally useful in determining enzyme phenotype, especially where a multiplicity of enzyme forms exist. This characterization of phenotype will be useful in defining the enzymatic basis for biochemical individuality. A library of monoclonal antibodies to cytochromes P-450, of which we report the first volumes, will serve to prepare an atlas of specific P450s in different species, strains, tissues, and individuals. These MAbs may be useful for studying genetic control, phylogenetic evolution, and the changing distribution of cytochromes P-450 during fetal and sexual development and after exposure to different inducers and in different nutritional states. Furthermore, the MAbs could be used for P-450 enzyme mechanism studies, for affinity column purification of P-450s and subsequent protein sequencing, and for defining P-450 
